Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CLIN
Clean Earth Acquisitions
$0.01
$6.76
$4.54
$11.36
$234K-0.1478,528 shs5.58 million shs
Concordia International Corp. stock logo
CXR
Concordia International
C$0.00
C$19.02
C$417.00
C$1.22BN/A4,054 shs73,541 shs
Endonovo Therapeutics, Inc. stock logo
ENDV
Endonovo Therapeutics
$0.00
+50.0%
$0.00
$0.00
$0.00
$240K-1.357.10 million shs166,770 shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CLIN
Clean Earth Acquisitions
-33.33%-51.01%-53.33%-32.69%-96.14%
Concordia International Corp. stock logo
CXR
Concordia International
0.00%0.00%0.00%0.00%0.00%
Endonovo Therapeutics, Inc. stock logo
ENDV
Endonovo Therapeutics
+50.00%+200.00%+200.00%0.00%-66.67%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CLIN
Clean Earth Acquisitions
N/AN/AN/AN/AN/AN/AN/AN/A
Concordia International Corp. stock logo
CXR
Concordia International
N/AN/AN/AN/AN/AN/AN/AN/A
Endonovo Therapeutics, Inc. stock logo
ENDV
Endonovo Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CLIN
Clean Earth Acquisitions
0.00
N/AN/AN/A
Concordia International Corp. stock logo
CXR
Concordia International
0.00
N/AN/AN/A
Endonovo Therapeutics, Inc. stock logo
ENDV
Endonovo Therapeutics
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CLIN
Clean Earth Acquisitions
N/AN/AN/AN/AN/AN/A
Concordia International Corp. stock logo
CXR
Concordia International
C$569.62M0.00N/A5.85C$6.08 per share0.00
Endonovo Therapeutics, Inc. stock logo
ENDV
Endonovo Therapeutics
$10K36.20$0.03 per share0.01($0.08) per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CLIN
Clean Earth Acquisitions
N/AN/A0.00N/AN/AN/AN/AN/A
Concordia International Corp. stock logo
CXR
Concordia International
N/AC$351.680.07N/AN/AN/AN/AN/AN/A
Endonovo Therapeutics, Inc. stock logo
ENDV
Endonovo Therapeutics
-$2.80MN/A0.00N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CLIN
Clean Earth Acquisitions
N/AN/AN/AN/AN/A
Concordia International Corp. stock logo
CXR
Concordia International
N/AN/AN/AN/AN/A
Endonovo Therapeutics, Inc. stock logo
ENDV
Endonovo Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CLIN
Clean Earth Acquisitions
N/AN/AN/A
Concordia International Corp. stock logo
CXR
Concordia International
457.02
2.10
1.66
Endonovo Therapeutics, Inc. stock logo
ENDV
Endonovo Therapeutics
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
CLIN
Clean Earth Acquisitions
26.39%
Concordia International Corp. stock logo
CXR
Concordia International
N/A
Endonovo Therapeutics, Inc. stock logo
ENDV
Endonovo Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
CLIN
Clean Earth Acquisitions
24.27%
Concordia International Corp. stock logo
CXR
Concordia International
N/A
Endonovo Therapeutics, Inc. stock logo
ENDV
Endonovo Therapeutics
5.61%
CompanyEmployeesShares OutstandingFree FloatOptionable
CLIN
Clean Earth Acquisitions
N/A16.70 million12.65 millionNot Optionable
Concordia International Corp. stock logo
CXR
Concordia International
22,50048.91 millionN/ANot Optionable
Endonovo Therapeutics, Inc. stock logo
ENDV
Endonovo Therapeutics
11.21 billion1.14 billionNot Optionable

Recent News About These Companies

Endonovo Therapeutics, Inc. (ENDV)
Lexeo Therapeutics Inc (LXEO)
Endonovo's SofPulse® Secures Taiwan FDA Approval

New MarketBeat Followers Over Time

Top Headlines

View All Headlines

Clean Earth Acquisitions NASDAQ:CLIN

Clean Earth Acquisitions Corp. does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It focuses on acquiring companies in the clean energy ecosystem, including carbon, hydrogen, sustainable agriculture, and renewable energy. The company was incorporated in 2021 and is based in Bee Cave, Texas.

Concordia International stock logo

Concordia International TSE:CXR

Concordia International Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies. This segment's products include Macrobid/Macrodantin to treat bladder infections, such as cystitis and urinary tract infections; Tetroxin drug for severe hypothyroid states; Eltroxin, levothyroxine sodium that treats patients with an underactive thyroid gland; and Fucithalmic, a topical gel treatment for patients suffering with a bacterial infection of the surface lining of the front of the eye. The Concordia North America segment provides Donnatalm, which is used as adjunctive therapy for irritable bowel syndrome; Zonegran, an anti-seizure drug indicated for adjunctive therapy in the treatment of partial seizures in adults with epilepsy; and Plaquenil and Plaquenil AG to treat rheumatoid arthritis and manage the complications of lupus, as well as suppress acute attacks from certain strains of malaria. This segment also offers photodynamic therapy with Photofrin for the treatment of certain forms of cancer that combines a photosensitizing agent with a specific type of laser that emits an exact wavelength of light and power to target cancer cells. The company sells its products through direct sales and local partnerships. The company was formerly known as Concordia Healthcare Corp. and changed its name to Concordia International Corp. in 2016. Concordia International Corp. is headquartered in Oakville, Canada.

Endonovo Therapeutics stock logo

Endonovo Therapeutics OTCMKTS:ENDV

$0.0003 +0.00 (+50.00%)
As of 07/10/2025 03:13 PM Eastern

Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.